Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1

Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer

(2020) Alaknanda Adwal et al.   Life Science Alliance

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

(2019) Lorenzo Castagnoli et al.   ONCOGENE

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

(2019) Zahraa Al-Hilli et al.   BREAST CANCER RESEARCH AND TREATMENT

Regulatory T cells: a potential target in cancer immunotherapy

(2018) Kohei Shitara et al.   Annals of the New York Academy of Sciences

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

(2018) Karina Kulangara et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype

(2018) Kenichi Harano et al.   PLoS One

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications

(2018) Amy Ellen McCart Reed et al.   JOURNAL OF PATHOLOGY

Predictive biomarkers for tumor immune checkpoint blockade

(2018) Mengting Tong et al.   Cancer Management and Research

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes

(2018) Nancy Tray et al.   BREAST

Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis

(2016) Jiafeng Shou et al.   BMC CANCER

Targeting regulatory T cells in tumors

(2016) Chang Liu et al.   FEBS Journal

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome

(2016) Rhiannon K Beckers et al.   HISTOPATHOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1

(2016) Upasana Joneja et al.   JOURNAL OF CLINICAL PATHOLOGY

PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient

(2016) Zhenhua Li et al.   Journal of Cancer

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Survival Outcomes of Metaplastic Breast Cancer Patients: Results from a US Population-based Analysis

(2014) Rebecca A. Nelson et al.   ANNALS OF SURGICAL ONCOLOGY

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic breast carcinomas display genomic and transcriptomic heterogeneity

(2014) Britta Weigelt et al.   MODERN PATHOLOGY

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

The prognostic significance of metaplastic carcinoma of the breast (MCB) – A case controlled comparison study with infiltrating ductal carcinoma

(2013) Hung-Wen Lai et al.   BREAST

Prognostic impact of FOXP3 expression in triple-negative breast cancer

(2012) Soohyeon Lee et al.   ACTA ONCOLOGICA

CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients

(2012) A. J. Rech et al.   Science Translational Medicine

β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast

(2010) Magali Lacroix-Triki et al.   MODERN PATHOLOGY

Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

(2009) B. T. Hennessy et al.   CANCER RESEARCH

Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis

(2008) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT